GLP-1 agonist · 6 min read

Semaglutide: Research Guide

The weekly shot (and now pill) behind Ozempic and Wegovy. It copies a gut hormone that curbs appetite, and large trials show it also protects the heart and kidneys and improves fatty liver disease.

Evidence
Approved indication
References
22 PubMed sources
Last reviewed
Status
Information only
Human evidence
AMany large randomized trials show major weight loss while people take it, plus fewer heart attacks, strokes and kidney problems.Large randomized trials in people show a benefit, or a regulator has approved it for a use.
FDA status
FDA-approved

Approved as Ozempic (type 2 diabetes, heart and kidney protection) and Wegovy (weight, heart risk, fatty liver disease). Compounded copies stopped being allowed after the shortage ended in 2025.

Sport (WADA)
Not named on WADA list

Not prohibited, but WADA is monitoring its use by athletes.

My experience
No personal experience yet

How well it has worked for me, from 1 to 10. One person's experience, not evidence, and not a recommendation or dosing advice.Read my experience →

Sources for these ratings are cited in the guide below, mainly in Legal status.

At a glance

Sequence
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys*-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly (*fatty-acid chain attached at lysine 26)
Molecular weight
≈4,114 Da
Formula
C187H291N45O59
Class
GLP-1 receptor agonist (31 amino acids)
Also known as
Ozempic · Wegovy · Rybelsus

What is semaglutide?

Semaglutide is a lab-made copy of GLP-1, a hormone your gut releases after you eat. Chemists changed two of its building blocks, one of them to protect it from being broken down, and attached a fatty-acid chain that clings to proteins in the blood. These changes help it last [1]: in people, it stays in the body for about a week [S1].

It’s one of the best-studied peptide medicines in the world. It’s sold as Ozempic for type 2 diabetes [S2] and as Wegovy for weight loss, heart protection and fatty liver disease [S1]. Wegovy comes as a weekly injection or a daily tablet [S1].

How might it work?

  • Turning down hunger. In a 20-week trial, people taking semaglutide ate 35% fewer calories at an all-you-can-eat meal than people on placebo. They felt less hungry and fuller, and reported fewer and weaker food cravings [2].
  • Not just a slow stomach. GLP-1 drugs are often said to work by slowing digestion. In that same trial, researchers found no clear slowing of stomach emptying after 20 weeks, which suggests the main effect is on appetite [2].
  • Lasting all week. Its long half-life of about one week is why one dose a week is enough [S1].

What has research found?

Weight loss

  • The landmark trial (STEP 1): In 1,961 adults without diabetes, people on semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo. Half lost at least 15% [3].
  • A higher dose: A newer, higher dose led to 18.7% weight loss, compared with 15.6% on the standard dose and 3.9% on placebo [4].
  • As a pill: A daily tablet led to 13.6% weight loss over 64 weeks, compared with 2.2% on placebo [5].

Keeping it off

  • Staying on it works. After 20 weeks on semaglutide, people who kept taking it lost another 7.9% over the next 48 weeks. People switched to placebo regained 6.9% [6].
  • Stopping brings weight back. A year after stopping, people had regained about two-thirds of the weight they’d lost. Most of the improvements in blood pressure, blood sugar and cholesterol faded too [7].

Heart, kidneys and liver

  • Heart attacks and strokes: In 17,604 adults with heart disease and overweight but no diabetes, semaglutide cut the risk of heart attack, stroke or death from heart disease by 20% over about three years (6.5% vs. 8.0%) [8]. An earlier trial in people with type 2 diabetes found a similar benefit [9].
  • Kidneys: In 3,533 people with type 2 diabetes and kidney disease, semaglutide lowered the risk of serious kidney events (kidney failure, a large drop in kidney function, or death from kidney or heart causes) by 24%, and the risk of death from any cause by 20%. The trial was stopped early on the advice of its independent monitors [10].
  • Fatty liver disease: In people with liver inflammation and scarring (MASH), the inflammation cleared in 63% of people on semaglutide, compared with 34% on placebo. Scarring improved in 37% vs. 22% [11].

Getting around

  • Heart failure: In people with obesity and a common type of heart failure, semaglutide eased symptoms and added about 20 meters to a six-minute walk compared with placebo [12].
  • Knee arthritis: Knee pain scores dropped by 41.7 points with semaglutide, compared with 27.5 on placebo [13].
  • Leg artery disease: In people with poor blood flow to the legs and type 2 diabetes, semaglutide let people walk about 13% farther than placebo after a year [14].

What didn’t work

  • Alzheimer’s disease: Two large trials in 3,808 people with early Alzheimer’s found that semaglutide tablets did not slow memory and thinking decline over two years [15]. A good reminder that a drug that helps one organ doesn’t automatically help them all.

For athletes: muscle and performance

  • Some of the weight lost is muscle. A review of 35 trials of semaglutide and similar drugs found that, across those drugs, a median of about 28% of the weight lost showed up as lost lean tissue (measures that include muscle), though it varied widely. None of those trials reported objective tests of physical function, such as strength [16].
  • Muscle quality may improve. In a small MRI study of 55 people, thigh muscle shrank slightly (too little to be sure it wasn’t chance), but the fat stored inside the muscle clearly dropped, and sit-to-stand reps didn’t drop. It was a small add-on study, mostly at the higher dose [17].
  • No studies in trained athletes. The trials above were in people with obesity or disease. We found no published studies of whether semaglutide helps or hurts endurance performance in fit people.
  • Not banned, but watched. Semaglutide isn’t on the 2026 banned list. The U.S. Anti-Doping Agency says GLP-1 drugs are not prohibited in sport, but the World Anti-Doping Agency is monitoring their use and could ban them in the future [S3, S4].

How strong is the evidence?

What we know so farWhat we still don’t know
It causes large, lasting weight loss while people keep taking it [3, 6]How to keep weight off after stopping [7]
It lowers the risk of heart attack, stroke and kidney failure in high-risk people [8, 10]How it affects strength and performance in fit, healthy people [16]
It improves fatty liver disease, knee pain and heart failure symptoms [11, 12, 13]How much the eye condition seen in some studies is truly caused by the drug [18, 19]
  • Very strong trials, one main sponsor. The key trials are large, randomized and placebo-controlled, the gold standard. Nearly all were funded by the manufacturer, Novo Nordisk [8, 10, 11].

Safety: what we know

  • Stomach upset is very common. In the main weight-loss trials, nausea affected 44% of people on semaglutide vs. 16% on placebo, diarrhea 30% vs. 16%, vomiting 25% vs. 6%, and constipation 24% vs. 11%. Most cases were mild to moderate and happened while the dose was being raised. About 4% stopped because of them [20].
  • People do stop. In the large heart trial, 16.6% stopped semaglutide because of side effects, compared with 8.2% on placebo [8].
  • Gallbladder problems. Across GLP-1 drugs, gallbladder problems were about 26% more common than with placebo [21]. The label also warns about pancreatitis [S1], though a large review of trials found no clear increase [21].
  • Thyroid tumors in rodents. Semaglutide caused thyroid tumors in rats and mice. It’s unknown whether this happens in people, but the label carries a boxed warning, and people with certain family histories of thyroid cancer shouldn’t use it [S1].
  • A rare eye condition. One study linked semaglutide to a sudden loss of vision in one eye called NAION [18]. A much larger study found a smaller increase in risk than first reported [19].
  • Mood. An observational study of health records from more than 240,000 people found a lower, not higher, risk of suicidal thoughts with semaglutide than with other weight-loss drugs [22]. In 2026, FDA removed the suicidal-thoughts warning from Wegovy’s label [S1].
  • Copies carry extra risk. By May 2026, FDA had received 990 reports of side effects from compounded semaglutide, some from dosing mistakes. It also warns that some sellers use different salt forms of the drug, and that “research use” products are of unknown quality [S5].
  • FDA-approved. Ozempic is approved for type 2 diabetes and to lower heart and kidney risks in people with diabetes [S2]. Wegovy is approved for weight loss, to lower heart risk, and for fatty liver disease with scarring [S1].
  • Compounding. FDA declared the semaglutide shortage over in February 2025. After a short wind-down that ended in spring 2025, pharmacies could no longer make copies of it under the shortage rules [S6].
  • Sports. Not banned, but under watch by anti-doping agencies [S3, S4].

The bottom line

Semaglutide is a peptide success story. A small tweak to a natural gut hormone produced a medicine that, in large trials, helps people lose about 15% of their body weight and lowers the risk of heart attacks, strokes and kidney failure.

It isn’t magic, though. Stomach side effects are common, some of the weight lost is muscle, and most of the weight returns after stopping. For athletes, it isn’t banned in sport for now, but we found no studies of what it does for fit, healthy people. The safest route is the approved product, prescribed and monitored by a clinician.

References

Peer-reviewed sources indexed in PubMed, numbered in order of first citation. Study type is shown so you can judge how directly each source applies to humans.

  1. 1

    Lau J, Bloch P, Schäffer L, et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem, 58(18):7370-80.

  2. 2

    Friedrichsen M, Breitschaft A, Tadayon S, et al. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab, 23(3):754-762.

  3. 3

    Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 384(11):989-1002.

  4. 4

    Wharton S, Freitas P, Hjelmesæth J, et al. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol, 13(11):949-963.

  5. 5

    Wharton S, Lingvay I, Bogdanski P, et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med, 393(11):1077-1087.

  6. 6

    Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14):1414-1425.

  7. 7

    Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab, 24(8):1553-1564.

  8. 8

    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med, 389(24):2221-2232.

  9. 9

    Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 375(19):1834-1844.

  10. 10

    Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med, 391(2):109-121.

  11. 11

    Sanyal AJ, Newsome PN, Kliers I, et al. (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med, 392(21):2089-2099.

  12. 12

    Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. (2023). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med, 389(12):1069-1084.

  13. 13

    Bliddal H, Bays H, Czernichow S, et al. (2024). Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med, 391(17):1573-1583.

  14. 14

    Bonaca MP, Catarig AM, Houlind K, et al. (2025). Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet, 405(10489):1580-1593.

  15. 15

    Cummings JL, Atri A, Sano M, et al. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet, 407(10544):2167-2179.

  16. 16

    Batsis JA, Gavras A, Gross DC, et al. (2026). Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review. Ann Intern Med, 179(7):996-1013.

  17. 17

    Hjelmesæth J, Bhat S, Garvey WT, et al. (2026). Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP. Diabetes Obes Metab.

  18. 18

    Hathaway JT, Shah MP, Hathaway DB, et al. (2024). Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol, 142(8):732-739.

  19. 19

    Cai CX, Hribar M, Baxter S, et al. (2025). Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmol, 143(4):304-314.

  20. 20

    Wharton S, Calanna S, Davies M, et al. (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab, 24(1):94-105.

  21. 21

    Galli M, Benenati S, Laudani C, et al. (2025). Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol, 86(20):1805-1819.

  22. 22

    Wang W, Volkow ND, Berger NA, et al. (2024). Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med, 30(1):168-176.

Regulatory & other sources

  1. S1

    Novo Nordisk, via U.S. National Library of Medicine (DailyMed). WEGOVY (semaglutide) injection and tablets: prescribing information (revised 06/2026). Accessed Nov 3, 2026.

  2. S2

    Novo Nordisk, via U.S. National Library of Medicine (DailyMed). OZEMPIC (semaglutide) injection: prescribing information. Accessed Nov 3, 2026.

  3. S3

    U.S. Anti-Doping Agency. Weight Loss Drugs: What Athletes Need to Know About GLP-1s. Accessed Nov 3, 2026.

  4. S4

    World Anti-Doping Agency (copy hosted by the International Testing Agency). World Anti-Doping Code International Standard: Prohibited List 2026. Accessed Nov 3, 2026.

  5. S5

    U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of Oct 1, 2026). Accessed Nov 3, 2026.

  6. S6

    U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of Apr 1, 2026). Accessed Nov 3, 2026.

Free weekly email + Scorecard PDF

Get the Friday Pep Brief

One short email every Friday: new research, FDA and anti-doping news, and scorecard changes. Subscribe and get the printable Peptide Evidence Scorecard free. Plain language, sources included. No sponsors, no vendor codes.

Unsubscribe anytime. See our privacy page.